CliffBio
small molecule

EPHEDRINE SULFATE

EPHEDRINE SULFATE

Loss of exclusivityFebruary 2026FDA regulatory exclusivity expiry
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameEPHEDRINE SULFATE
Active ingredientEPHEDRINE SULFATE
Strength50MG/10ML (5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
PCFebruary 2026

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

EPHEDRINE SULFATE patent cliff — loss of exclusivity February 2026 | CliffBio